GeniVida Impresses in Women's Health and Bone Health

New research has been presented at the 9th International Soy Symposium, linking the soy isoflavone genistein to improved biomarkers in women's health and bone health.

In recent years, soy genistein has received attention in clinical science for its ability to curb symptoms of menopause, including the incidence of hot flashes and  bone degradation that may result from loss of estrogen, postmenopause. Now, two new studies have strengthened these arguments.

The studies were conducted with 30 mg of geniVida, a patented soy genistein by DSM Nutritional Products (Parsippany, NJ).

In one study, 84 healthy women were assigned to geniVida or placebo for 12 weeks while incidence of hot flashes was recorded. At 12 weeks, women taking geniVida experienced an average 51% reduction of hot flashes and 88% of these women reported a reduction to some degree. These results complement a previous unaffiliated study, published in the Journal of Obstetrics and Gynaecology Research, in which 60 mg of genistein reduced hot flashes by 41% compared to placebo, after 12 weeks.

Menopause also puts women at high risk of osteoporosis (due to loss of estrogen), although the condition is not sex-specific. In a second study, 58 postmenopausal women were assigned to geniVida Bone Blend (a combination product of geniVida, ROPUFA brand omega-3 fatty acids, and vitamins D3 and K1) or placebo for six months. Bone tissue status was observed in the femoral neck bones of patients.

At the end of the study, geniVida resulted in improved bone mineral density by 3.4% compared to placebo, along with the complete stopping of bone loss in this target area.

GeniVida is the active ingredient in i-Cool, a common consumer menopause product.

For more information on geniVida, visit DSM Nutritional Products.